DXM FAQ 1997: clarifying substance interactions

Nine statements about substance interactions from William E. White’s DXM FAQ, with current clarifications. Each comparison starts with the current interpretation, followed by a historical paraphrase.

FAQ 1997 → current commentary

Current clarifications

MDMA, MDA and 2C-B

Current clarification

Interaction mechanisms differ among substances within a chemical class. MDMA has direct pharmacokinetic interaction data.

Historical statement · paraphrase

MDMA, MDA, and 2C-B grouped as phenethylamines

Row in the review · row 1

Opioids

Current clarification

Separate respiratory and serotonergic mechanisms

Historical statement · paraphrase

Opioids treated as one class

Row in the review · row 2

Ketamine

Current clarification

Inadequate explanation; quantitative interaction remains poorly studied

Historical statement · paraphrase

Ketamine largely displaces DXM effects because of a shared binding site

Row in the review · row 3

Nitrous oxide (N₂O)

Current clarification

Subjective potentiation is plausible; absence of physical hazard is not established

Historical statement · paraphrase

N2O potentiates DXM without additional adverse effects

Row in the review · row 4

Ethanol and NMDA

Current clarification

No clinical basis to regard them as prevention of injury

Historical statement · paraphrase

Ethanol or other agents protect against presumed NMDA-related neurotoxicity

Row in the review · row 5

Yohimbine

Current clarification

Such injury is not established in humans; assess autonomic stress instead

Historical statement · paraphrase

Yohimbine produces Olney’s lesions with DXM

Row in the review · row 6

Nicotine and tobacco smoke

Current clarification

Nicotine and tobacco smoke differ. Reduced MAO activity has been described in smokers; prescribed MAOI exposure occurs under different conditions.

Historical statement · paraphrase

Cigarettes can be treated as nicotine or as a conventional MAOI

Row in the review · row 7

Sedating antihistamines

Current clarification

Consider chlorphenamine’s SERT effects, sedation, anticholinergic effects, and possible CYP inhibition

Historical statement · paraphrase

Sedating antihistamines are neutral additions

Row in the review · row 8

Subjective tolerability

Current clarification

It does not exclude hyperthermia, arrhythmias, aspiration, or altered exposure

Historical statement · paraphrase

Good subjective tolerability establishes safety

Row in the review · row 9

Reassessing FAQ statements

This review reassesses the interaction claims in William E. White’s *The Dextromethorphan FAQ*, Text Version 4.0 (1997), particularly Section 13 [1], against human studies, prescribing information, clinical reports, and scientific reviews. Targeted searches of accessible scientific and regulatory sources were conducted on 2 October 2026. Topics included CYP2D6, MDMA, serotonin toxicity, opioids, cannabinoids, MAOIs, antihistamines, and other dissociatives.

The historical Olney's lesions hypothesis

The Olney’s lesions hypothesis belongs to the historical discussion. The grounds for numerical ratings are given in the individual combination descriptions. Injury during severe intoxication is a broader question than this hypothesis.

An example: chemical classification and interaction

Interaction mechanisms differ among substances within a chemical class. MDMA has direct pharmacokinetic interaction data.

Comparison summary

Historical explanations and current evidential grounds can differ.

Sources

Reference

Open the source and related combinations →